https://briefpharma.com/roche-licenses-hanmis-muscle-sparing-obesity-drug/ 2026-08-25T17:36:58+00:00 https://briefpharma.com/ambros-and-werewolf-agree-550m-reverse-merger/ 2026-08-25T17:34:15+00:00 https://briefpharma.com/bluerock-automates-cell-therapy-analytics/ 2026-08-20T17:08:49+00:00 https://briefpharma.com/network-bio-launches-with-50m-financing/ 2026-08-21T16:44:47+00:00 https://briefpharma.com/merck-and-moderna-score-phase-3-vaccine-success/ 2026-08-20T16:43:54+00:00 https://briefpharma.com/biomarin-to-acquire-alesta-for-oral-hpp-drug/ 2026-08-20T16:42:04+00:00 https://briefpharma.com/leica-biosystems-to-acquire-statlab-medical-products/ 2026-07-21T16:33:09+00:00 https://briefpharma.com/circio-and-avenue-biosciences-team-up-on-engineered-circrna/ 2026-07-21T15:50:48+00:00 https://briefpharma.com/cellares-and-sonoma-biotherapeutics-automate-sbt-77-7101/ 2026-07-21T15:43:50+00:00 https://briefpharma.com/cellares-and-papillon-partner-to-automate-ppl-001-manufacturing/ 2026-07-21T15:11:58+00:00 https://briefpharma.com/advancell-raises-315-million-for-pluvicto-challenger-buildout/ 2026-07-16T15:57:56+00:00 https://briefpharma.com/astrazeneca-licenses-dizals-egfr-exon-20-lung-cancer-drug/ 2026-07-16T14:02:14+00:00 https://briefpharma.com/celcuity-wins-fda-approval-for-revtorpyk/ 2026-07-16T13:59:01+00:00 https://briefpharma.com/insilico-and-china-medical-system-expand-cns-push/ 2026-07-13T15:05:28+00:00 https://briefpharma.com/astrazeneca-licences-china-copd-molecule/ 2026-07-13T15:00:10+00:00 https://briefpharma.com/bioarctic-and-lilly-join-braintransporter/ 2026-06-25T19:22:01+00:00 https://briefpharma.com/lilly-expands-discovery-pact-with-abbisko/ 2026-06-25T19:16:19+00:00 https://briefpharma.com/bionyra-launches-with-165m-for-tl1a-drugs/ 2026-06-23T15:24:56+00:00 https://briefpharma.com/insilico-and-sk-bio-sign-2-5b-ai-discovery-deal/ 2026-06-23T15:21:14+00:00 https://briefpharma.com/abbvie-to-buy-apogee-therapeutics/ 2026-06-23T15:09:08+00:00 https://briefpharma.com/jazz-and-abcellera-sign-t-cell-engager-deal/ 2026-06-22T15:37:13+00:00 https://briefpharma.com/biogen-to-buy-raythera-for-up-to-1b/ 2026-06-22T14:34:56+00:00 https://briefpharma.com/sun-pharma-to-buy-innovcare-lifesciences/ 2026-06-22T14:19:40+00:00 https://briefpharma.com/fda-and-amgen-split-over-tavneos-data/ 2026-06-15T15:24:58+00:00 https://briefpharma.com/caribou-backs-off-the-shelf-car-t-with-new-data/ 2026-06-12T15:05:03+00:00 https://briefpharma.com/gen1e-wins-fda-designations-for-dmd-drug/ 2026-06-12T15:01:09+00:00 https://briefpharma.com/kardigan-targets-320m-nasdaq-listing/ 2026-06-12T14:54:44+00:00 https://briefpharma.com/sonothera-raises-125m-in-series-b/ 2026-06-11T14:29:25+00:00 https://briefpharma.com/novartis-signs-1-4b-orionis-collaboration/ 2026-06-11T14:22:32+00:00 https://briefpharma.com/wuxi-apptec-added-to-pentagon-military-list/ 2026-06-11T14:11:16+00:00 https://briefpharma.com/standard-biotools-merges-with-treeline/ 2026-06-09T21:16:33+00:00 https://briefpharma.com/astrazeneca-advances-oral-glp-1-drug/ 2026-06-09T21:02:17+00:00 https://briefpharma.com/gsk-to-buy-nuvalent-for-10-6b/ 2026-06-09T20:52:57+00:00 https://briefpharma.com/gsk-backs-engitix-with-44m-fibrosis-pact/ 2026-06-09T14:35:32+00:00 https://briefpharma.com/roche-and-nurix-strike-700m-btk-degrader-deal/ 2026-06-09T14:31:26+00:00 https://briefpharma.com/incyte-to-buy-vega-therapeutics-for-1-25b/ 2026-06-09T14:00:41+00:00 https://briefpharma.com/alnylam-and-inceptive-sign-ai-sirna-deal/ 2026-06-05T12:58:40+00:00 https://briefpharma.com/parabilis-sets-up-413m-ipo-for-phase-3-desmoid-trial/ 2026-06-05T12:56:34+00:00 https://briefpharma.com/lilly-and-ascidian-strike-1-9b-rna-pact/ 2026-06-04T17:41:27+00:00 https://briefpharma.com/cellares-and-tscan-explore-automated-tsc-101-manufacturing/ 2026-06-03T13:09:58+00:00 https://briefpharma.com/cingulate-hit-with-fda-rejection-over-manufacturing/ 2026-06-03T13:06:30+00:00 https://briefpharma.com/contraline-raises-92-5m-for-male-contraception/ 2026-06-03T13:00:00+00:00 https://briefpharma.com/servier-expands-rare-disease-push-with-2-6b-edgewise-deal/ 2026-06-01T14:24:51+00:00 https://briefpharma.com/pfizer-innovent-cancer-deal-worth-10-5b/ 2026-06-01T14:21:34+00:00 https://briefpharma.com/lilly-buys-three-vaccine-firms-in-3-8b-deal/ 2026-06-01T13:59:09+00:00 https://briefpharma.com/parabilis-files-for-ipo-after-800m-funding/ 2026-05-22T14:36:18+00:00 https://briefpharma.com/concept-and-openbench-launch-ai-discovery-deal/ 2026-05-22T14:26:52+00:00 https://briefpharma.com/astrazeneca-expands-immunai-ai-partnership/ 2026-05-22T14:15:17+00:00 https://briefpharma.com/20n-bio-raises-7-5m-seed-round/ 2026-05-21T13:20:44+00:00 https://briefpharma.com/benchling-and-baseten-bring-ai-inference-to-biotech-rd/ 2026-05-21T13:14:46+00:00 https://briefpharma.com/bristol-myers-deepens-ai-push-with-anthropic-partnership/ 2026-05-21T13:08:07+00:00 https://briefpharma.com/biomarin-hits-setback-in-rare-disease-phase-3/ 2026-05-19T15:25:11+00:00 https://briefpharma.com/regeneron-parabilis-form-2-3b-adc-like-pact/ 2026-05-19T15:21:40+00:00 https://briefpharma.com/create-medicines-raises-122m-for-in-vivo-car-t/ 2026-05-15T13:35:27+00:00 https://briefpharma.com/vetter-starts-construction-on-e500m-saarlouis-injectable-drug-facility/ 2026-05-15T13:31:24+00:00 https://briefpharma.com/bora-buys-macrogenics-facility-for-122-5m/ 2026-05-15T13:26:24+00:00 https://briefpharma.com/metis-techbio-goes-public-with-270m-for-ai-nanodelivery/ 2026-05-13T21:08:57+00:00 https://briefpharma.com/rigel-licenses-veppanu-breast-cancer-drug/ 2026-05-13T21:01:54+00:00 https://briefpharma.com/boehringer-pays-e407m-for-immunitas-asset/ 2026-05-13T13:29:14+00:00 https://briefpharma.com/bms-and-hengrui-strike-15-2b-alliance/ 2026-05-13T13:25:40+00:00 https://briefpharma.com/isomorphic-labs-raises-2-1b-in-series-b/ 2026-05-13T13:23:06+00:00 https://briefpharma.com/odyssey-raises-304m-in-upsized-ipo/ 2026-05-11T17:59:27+00:00 https://briefpharma.com/cellares-protgen-partner-on-prot-096/ 2026-05-11T17:52:52+00:00 https://briefpharma.com/angelini-buys-catalyst-pharma-for-4-1b/ 2026-05-08T13:03:18+00:00 https://briefpharma.com/banyan-bioinnovations-debuts-with-100m-and-icon/ 2026-05-08T12:56:44+00:00 https://briefpharma.com/blackstone-invests-250m-in-anagram/ 2026-05-07T23:16:30+00:00 https://briefpharma.com/cellcentric-funds-pivotal-myeloma-trials-with-220m/ 2026-05-06T21:52:36+00:00 https://briefpharma.com/gsk-bolsters-sirna-portfolio-with-siranbio-deal/ 2026-05-06T21:43:14+00:00 https://briefpharma.com/bayer-acquires-perfuse-for-2-45b/ 2026-05-06T21:37:42+00:00 https://briefpharma.com/sanofi-expands-toronto-ai-hub-with-294m/ 2026-05-06T13:21:17+00:00 https://briefpharma.com/cytospire-secures-83m-for-cancer-engagers/ 2026-05-06T13:17:13+00:00 https://briefpharma.com/ucb-acquires-candid-for-2-2b/ 2026-05-06T13:12:55+00:00 https://briefpharma.com/autolus-targets-profitability-with-cost-cuts/ 2026-05-01T12:58:10+00:00 https://briefpharma.com/leo-pharma-moves-into-gene-therapy-with-replay/ 2026-05-01T12:50:35+00:00 https://briefpharma.com/az-takes-full-control-of-pinetree-egfr-degrader/ 2026-04-30T19:12:35+00:00 https://briefpharma.com/vivacta-bio-raises-50m-for-car-t/ 2026-04-30T13:27:12+00:00 https://briefpharma.com/teva-buys-emalex-for-900m-tourette-drug/ 2026-04-30T13:24:40+00:00 https://briefpharma.com/axtria-langchain-partner-on-ai-agents/ 2026-04-30T13:22:23+00:00 https://briefpharma.com/chiesi-to-buy-kalvista-for-1-9b/ 2026-04-29T22:08:39+00:00 https://briefpharma.com/remepy-partners-with-merck-on-hybrid-drugs/ 2026-04-28T19:53:03+00:00 https://briefpharma.com/coultreon-secures-125m-for-autoimmune-pipeline/ 2026-04-28T18:48:43+00:00 https://briefpharma.com/cellares-and-cabaletta-bio-sign-supply-deal/ 2026-04-28T13:18:53+00:00 https://briefpharma.com/ligand-xoma-merger-builds-royalty-giant/ 2026-04-27T21:17:04+00:00 https://briefpharma.com/astellas-thins-pipeline-halts-at132/ 2026-04-27T19:56:18+00:00 https://briefpharma.com/jj-says-ai-is-speeding-drug-development/ 2026-04-27T19:24:05+00:00 https://briefpharma.com/kurma-secures-e215m-for-biotech-investments/ 2026-04-24T15:24:30+00:00 https://briefpharma.com/accenture-backs-iridius-for-life-sciences-ai/ 2026-04-23T20:43:27+00:00 https://briefpharma.com/first-gene-therapy-approved-for-hearing-loss/ 2026-04-23T20:38:52+00:00 https://briefpharma.com/ai-drug-discovery-set-to-hit-160b-by-2035/ 2026-04-22T20:52:48+00:00 https://briefpharma.com/merck-taps-google-cloud-for-ai-transformation/ 2026-04-22T20:52:18+00:00 https://briefpharma.com/private-equity-buys-cro-celerion-in-1-8b-deal/ 2026-04-22T20:39:32+00:00 https://briefpharma.com/serif-targets-safer-dna-therapeutics/ 2026-04-22T15:58:10+00:00 https://briefpharma.com/tortugas-emerges-with-106m-neuro-pipeline/ 2026-04-22T14:27:14+00:00 https://briefpharma.com/virica-debuts-viric-ai-for-biomanufacturing-optimisation/ 2026-04-22T14:17:36+00:00 https://briefpharma.com/biogen-secures-worldwide-felzartamab-rights/ 2026-04-21T12:48:43+00:00 https://briefpharma.com/lilly-bets-7b-on-kelonias-in-vivo-car-t-tech/ 2026-04-21T12:45:17+00:00 https://briefpharma.com/boehringers-150m-london-computational-innovation-hub/ 2026-04-21T12:39:35+00:00 https://briefpharma.com/agc-builds-350m-yokohama-cdmo-site/ 2026-04-20T20:26:07+00:00 https://briefpharma.com/litmys-and-konovo-team-up-for-rd-intelligence/ 2026-04-20T16:15:17+00:00 https://briefpharma.com/openai-launches-gpt-rosalind-for-life-sciences-research/ 2026-04-20T16:07:50+00:00 https://briefpharma.com/replimune-cuts-staff-after-second-rp1-rejection/ 2026-04-15T15:14:32+00:00 https://briefpharma.com/neomorph-secures-100m-series-b/ 2026-04-15T14:58:26+00:00 https://briefpharma.com/novo-nordisk-to-roll-out-openai-across-operations/ 2026-04-15T14:46:46+00:00 https://briefpharma.com/oricell-secures-110m-pre-ipo-for-stem-cell-pipeline/ 2026-04-14T14:10:54+00:00 https://briefpharma.com/regeneron-enters-radiopharma-via-2-1b-telix-deal/ 2026-04-14T14:09:03+00:00 https://briefpharma.com/vivatides-raises-54m-for-rna-delivery/ 2026-04-14T13:59:48+00:00 https://briefpharma.com/lillys-foundayo-approval-ignites-oral-glp-1-showdown/ 2026-04-09T21:15:58+00:00 https://briefpharma.com/gilead-pays-kymera-45m-for-cdk2-degrader/ 2026-04-09T20:58:44+00:00 https://briefpharma.com/c4-therapeutics-expands-roche-dac-deal/ 2026-04-09T20:55:15+00:00 https://briefpharma.com/welo-life-sciences-debuts-as-integrated-b2b-services-brand/ 2026-04-08T20:23:53+00:00 https://briefpharma.com/sidewinder-banks-137m-series-b-for-adc-development/ 2026-04-08T20:21:21+00:00 https://briefpharma.com/astellas-licenses-dyno-capsid-for-muscle-gene-therapy/ 2026-04-08T20:19:02+00:00 https://briefpharma.com/neurocrine-acquires-soleno-for-2-9b-rare-obesity-asset/ 2026-04-07T19:03:10+00:00 https://briefpharma.com/anthropic-expands-to-ai-drug-discovery-with-400m-buy/ 2026-04-07T16:41:42+00:00 https://briefpharma.com/gilead-to-buy-tubulis-in-oncology-adc-deal/ 2026-04-07T15:57:11+00:00 https://briefpharma.com/sononeu-exits-stealth-with-41-3m-arpa-h-award/ 2026-04-07T15:56:53+00:00 https://briefpharma.com/teva-prolia-biosimilar-gets-fda-green-light/ 2026-04-02T11:59:05+00:00 https://briefpharma.com/biogen-advances-in-lupus-with-data-and-approval/ 2026-04-02T11:49:48+00:00 https://briefpharma.com/merck-inks-838m-pact-with-antibody-specialist-infinimmune/ 2026-03-31T20:25:06+00:00 https://briefpharma.com/ambrosia-biosciences-bags-100m-to-bring-oral-glp-1-to-clinic/ 2026-03-31T20:09:20+00:00 https://briefpharma.com/lilly-pays-6-3b-for-centessas-orexin-sleep-programme/ 2026-03-31T19:57:17+00:00 https://briefpharma.com/astrazeneca-posts-strong-copd-phase-3-data/ 2026-03-31T13:05:21+00:00 https://briefpharma.com/eli-lilly-partners-insilico-in-2-75b-ai-drug-pact/ 2026-03-31T12:56:07+00:00 https://briefpharma.com/gilead-acquires-ouro-medicines-in-2-2b-deal/ 2026-03-31T12:49:55+00:00 https://briefpharma.com/private-equity-tables-e10-9bn-bid-for-recordati/ 2026-03-29T11:07:16+00:00 https://briefpharma.com/otsuka-buys-transcend-in-1-2b-mdma-deal/ 2026-03-29T11:01:14+00:00 https://briefpharma.com/novartis-buys-excellergy-for-up-to-2b/ 2026-03-29T10:52:37+00:00 https://briefpharma.com/matica-lands-adenovirus-therapy-cdmo-contract/ 2026-03-27T15:10:38+00:00 https://briefpharma.com/mhra-considers-permanent-ce-mark-access-for-gb-devices/ 2026-03-27T15:00:37+00:00 https://briefpharma.com/merck-acquires-terns-for-6-7b-to-secure-best-in-class-cml-drug/ 2026-03-26T15:19:24+00:00 https://briefpharma.com/abbott-completes-acquisition-of-exact-sciences/ 2026-03-25T17:08:50+00:00 https://briefpharma.com/merck-and-quotient-strike-ibd-deal/ 2026-03-24T23:45:34+00:00 https://briefpharma.com/aardvark-halts-obesity-studies-after-data-miss/ 2026-03-24T23:31:09+00:00 https://briefpharma.com/novartis-ramps-up-china-investment-with-multi-site-expansion-plan/ 2026-03-24T15:24:38+00:00 https://briefpharma.com/esteve-cdmo-to-expand-celra-site-with-new-spray-drying-unit-by-2027/ 2026-03-24T15:20:27+00:00 https://briefpharma.com/cambrex-preps-new-large-scale-api-plant-in-iowa/ 2026-03-24T13:34:58+00:00 https://briefpharma.com/compass-pathways-second-psilocybin-win/ 2026-03-22T00:01:02+00:00 https://briefpharma.com/innovacell-eyes-92m-tokyo-ipo/ 2026-03-21T21:47:14+00:00 https://briefpharma.com/gilead-genhouse-bio-sign-1-5b-synthetic-lethal-pact/ 2026-03-21T21:20:13+00:00 https://briefpharma.com/lgm-boosts-us-cdmo-capacity/ 2026-03-20T16:08:20+00:00 https://briefpharma.com/esteve-builds-new-api-unit-in-celra/ 2026-03-19T21:39:29+00:00 https://briefpharma.com/syneos-expands-in-china-via-bestudy-buy/ 2026-03-19T21:34:12+00:00 https://briefpharma.com/thalia-therapeutics-emerges-from-n4-rebrand/ 2026-03-19T17:27:39+00:00 https://briefpharma.com/rapport-tenacia-deal-funds-rap-219-phase-3/ 2026-03-19T17:21:13+00:00 https://briefpharma.com/mestag-nets-40m-to-take-mst-0312-into-clinic/ 2026-03-19T17:19:12+00:00 https://briefpharma.com/fda-rejects-aldeyra-reproxalap-third-time/ 2026-03-17T22:08:47+00:00 https://briefpharma.com/xaira-unveils-ai-drug-discovery-approach/ 2026-03-17T22:01:54+00:00 https://briefpharma.com/bicycle-therapeutics-cuts-30-workforce/ 2026-03-17T22:01:02+00:00 https://briefpharma.com/bayer-preps-kerendia-ckd-label-expansion/ 2026-03-16T20:48:04+00:00 https://briefpharma.com/vistagen-cuts-20-staff-for-cns-focus/ 2026-03-16T20:41:15+00:00 https://briefpharma.com/agilent-to-acquire-biocare-medical-for-950m-in-cash/ 2026-03-16T20:37:10+00:00 https://briefpharma.com/samsung-biologics-and-lilly-to-launch-gateway-labs-korea/ 2026-03-15T22:52:54+00:00 https://briefpharma.com/fda-extends-gsks-arexvy-use-to-younger-at-risk-adults/ 2026-03-15T22:49:12+00:00 https://briefpharma.com/agilent-launches-advanced-therapeutics-cdmo/ 2026-03-12T21:27:57+00:00 https://briefpharma.com/stryker-cyberattack-disrupts-networks/ 2026-03-12T21:21:26+00:00 https://briefpharma.com/locus-cell-partners-charles-river-on-cgt/ 2026-03-12T21:18:51+00:00 https://briefpharma.com/xcath-raises-30m-for-neuro-robot/ 2026-03-12T13:27:11+00:00 https://briefpharma.com/fujifilm-invests-in-valanx-adc-cdmo/ 2026-03-12T13:05:19+00:00 https://briefpharma.com/medtronic-buys-scientia-vascular-for-550m/ 2026-03-12T13:00:50+00:00 https://briefpharma.com/genedx-enables-faster-npc-diagnosis/ 2026-03-10T22:20:38+00:00 https://briefpharma.com/biontech-founders-to-launch-mrna-startup/ 2026-03-10T22:15:39+00:00 https://briefpharma.com/xenon-epilepsy-drug-beats-expectations/ 2026-03-10T22:09:31+00:00 https://briefpharma.com/ascendis-yuviwel-wins-fda-ok-in-achondroplasia/ 2026-03-10T13:49:50+00:00 https://briefpharma.com/cognito-raises-105m-for-alzheimers-device/ 2026-03-09T23:26:19+00:00 https://briefpharma.com/tenacia-rapport-strike-308m-china-epilepsy-deal/ 2026-03-09T23:21:04+00:00 https://briefpharma.com/beam-restructures-partner-deal-for-tech-rights/ 2026-03-08T21:56:04+00:00 https://briefpharma.com/fda-cracks-down-on-compounded-glp-1s/ 2026-03-08T21:54:20+00:00 https://briefpharma.com/servier-to-acquire-day-one-and-ojemda-for-2-5b-cash/ 2026-03-08T21:54:00+00:00 https://briefpharma.com/medtronic-ge-expand-monitoring-alliance/ 2026-03-05T22:18:23+00:00 https://briefpharma.com/theolytics-secures-e8m-ovarian-cancer-grant/ 2026-03-05T22:11:28+00:00 https://briefpharma.com/tenaya-alnylam-gene-target-discovery-pact/ 2026-03-05T22:06:47+00:00 https://briefpharma.com/fda-lifts-holds-on-intellia-crispr-trials/ 2026-03-04T21:56:21+00:00 https://briefpharma.com/boehringer-ends-mash-deal-with-ose/ 2026-03-04T21:53:18+00:00 https://briefpharma.com/disc-medicine-lays-off-20-post-fda-rejection/ 2026-03-04T21:50:35+00:00 https://briefpharma.com/glp1/ 2026-03-03T21:30:58+00:00 https://briefpharma.com/mark-foundation-funds-2026-drug-discovery/ 2026-03-03T21:16:46+00:00 https://briefpharma.com/theravance-axes-rd-post-trelegy-asthma-miss/ 2026-03-03T21:12:23+00:00 https://briefpharma.com/droplet-uses-nvidia-for-rapid-cancer-tests/ 2026-03-03T21:10:38+00:00 https://briefpharma.com/candid-goes-public-via-rallybio-merger/ 2026-03-02T22:48:48+00:00 https://briefpharma.com/roche-fenebrutinib-wins-phase-3-ms-trial/ 2026-03-02T22:48:00+00:00 https://briefpharma.com/congruence-ono-add-two-targets-to-ai-pact/ 2026-03-02T22:45:48+00:00 https://briefpharma.com/generate-biomedicines-debuts-with-400m-ipo-raise/ 2026-03-01T01:29:56+00:00 https://briefpharma.com/tevogen-signs-loi-for-cro-acquisition/ 2026-03-01T01:26:42+00:00 https://briefpharma.com/atrium-therapeutics-spins-out-with-270m-and-two-cardio-sirnas/ 2026-03-01T01:06:42+00:00 https://briefpharma.com/bms-adc-bl-b01d1-hits-phase-3-endpoints/ 2026-02-26T21:42:20+00:00 https://briefpharma.com/asahi-kasei-buys-aicuris-for-920m/ 2026-02-26T21:21:39+00:00 https://briefpharma.com/blue-arbor-gets-5m-ottobock-investment/ 2026-02-26T21:10:22+00:00 https://briefpharma.com/charles-river-divests-cdmo-assets/ 2026-02-25T22:42:22+00:00 https://briefpharma.com/gsk-buys-35pharma-for-950m-pah-drug/ 2026-02-25T22:32:56+00:00 https://briefpharma.com/novo-inks-2-1b-vivtex-oral-biologics-deal/ 2026-02-25T22:31:30+00:00 https://briefpharma.com/novo-cuts-wegovy-prices-50-from-2027/ 2026-02-24T20:31:03+00:00 https://briefpharma.com/slate-targets-migraine-with-130m-pacap-funding/ 2026-02-24T20:28:11+00:00 https://briefpharma.com/harbour-biomed-secures-1-1b-biobucks-partnership/ 2026-02-24T20:22:04+00:00 https://briefpharma.com/fortress-sells-prv-for-205m-post-zycubo-approval/ 2026-02-23T21:38:22+00:00 https://briefpharma.com/bora-lands-250m-biologics-deal-with-gsk/ 2026-02-23T21:34:20+00:00 https://briefpharma.com/gilead-to-buy-arcellx-in-8b-car-t-deal/ 2026-02-23T21:30:15+00:00 https://briefpharma.com/grails-galleri-trial-fails-key-endpoint/ 2026-02-20T19:45:32+00:00 https://briefpharma.com/court-halts-trumps-emergency-tariffs-amid-pharma-relief/ 2026-02-20T19:43:23+00:00 https://briefpharma.com/candel-secures-100m-rtw-cancer-launch-funding/ 2026-02-20T19:40:05+00:00 https://briefpharma.com/cocrystals-cdi-988-enters-norovirus-challenge-trial/ 2026-02-19T21:55:41+00:00